PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15920862

Partial dopamine agonists in schizophrenia.

Mike Launer
View original source ↗Export metadata ↓

Abstract

The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia.

Explore related subjects

AripiprazoleClinical Trials as TopicDopamine AgonistsHumansPiperazinesQuinolonesSchizophreniaTreatment OutcomeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mike Launer. 2005. Partial dopamine agonists in schizophrenia.. https://doi.org/10.12968/hmed.2005.66.5.18426

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma.

An accurate, sensitive, reproducible, and selective liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for determination of aripiprazole and its main metabolite, OPC-14857, in human plasma was developed and validated. Chromatographic separation was achieved isocratically on a C18 reversed-phase column within 7.5 min. The calibration curve, ranging from 0.1 to 100 ng/ml, was fitted to a 1/y2-weighted linear regression model. The assay showed no significant interference. Lower limit of quantitation (LLOQ) for both analytes was 0.1 ng/ml using 0.4 ml of plasma. Intra- and inter-assay precision and accuracy values for aripiprazole and OPC-14857 were within regulatory limits.

Aripiprazole↗
PubMed2005

TrkB partial agonists: potential treatment strategy for epilepsy, mania, and autism.

Brain-derived neurotrophic factor (BDNF) is a member of a family of neurotrophins that, by activating a tyrosine kinase B receptor (TrkB), regulates a wide variety of processes in the nervous system, including neural development, function and survival. Evidence suggests that excess BDNF is involved in the pathogenesis of epilepsy, mania and autism. Thus, agents that can decrease BDNF-TrkB pathway signaling may be therapeutic for these diseases. However, blocking BDNF-TrkB pathways with TrkB antagonists may be harmful, as BDNF-TrkB deficiency has been related to major depression and Alzheimer's disease. A partial agonist is an agent that elicits a maximum response that is less than that of an agonist (e.g., the physiological ligand), so, in the presence of excess full agonist, a partial agonist would act as an antagonist. Interestingly, a dopaminergic partial agonist, aripiprazole, has been successfully developed for the treatment of psychotic disorders. Recently specific TrkB partial agonists have been synthesized by O'Leary and Hughes; it is proposed that these partial TrkB agonists may provide a novel strategy for the treatment of epilepsy, mania or autism, which may be associated with BDNF-TrkB hyperfunction.

Aripiprazole↗